Centessa Pharmaceuticals Shares Exciting Phase 1 Data for ORX750
Exciting Developments from Centessa Pharmaceuticals
In an exciting announcement, Centessa Pharmaceuticals plc (NASDAQ: CNTA), a clinical-stage pharmaceutical company, has disclosed that it will present data from the Phase 1 clinical trial of its investigational drug, ORX750. This drug is an innovative orexin receptor 2 (OX2R) agonist that shows promise in treating various sleep-wake disorders, including narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2).
Overview of the Upcoming Presentation
The Phase 1 clinical trial data will be shared in a poster presentation at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, scheduled to take place from April 5-9, 2025. Centessa's commitment to advancing treatments for sleep-related conditions is underscored by their rigorous research and development efforts in this area.
Details of the Presentation
During this poster session, Centessa will provide an overview of the Phase 1 clinical data regarding ORX750. This novel compound is characterized as a highly potent and selective OX2R agonist, designed to aid patients suffering from NT1, NT2, and idiopathic hypersomnia (IH). The presentation, highlighting key findings and insights from the study, is anticipated to garner significant attention from the neuroscientific community.
Poster Presentation Details:
Title: Phase 1 Clinical Data with Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Participants
Abstract Number: 2277
Presenter: Deborah Hartman, PhD, Global Scientific Head, Orexin Program
Session Date and Time: Saturday, April 5, 2025, at 11:45 AM - 12:45 PM PT
Importance of ORX750
ORX750 stands out in Centessa's pipeline due to its targeted approach to mitigating the challenges faced by individuals suffering from significant sleep disturbances. The potential applications of this compound extend beyond merely treating narcolepsy; it is also being investigated for its effectiveness against excessive daytime sleepiness that often accompanies neurological and psychiatric conditions.
Current Trials and Future Directions
Currently, Centessa is advancing ORX750 through an ongoing Phase 2a clinical trial, referred to as CRYSTAL-1, which focuses on participants diagnosed with NT1, NT2, and IH. This research aims to elucidate the safety, tolerability, and efficacy of the drug, providing a solid foundation for subsequent studies and further development.
Centessa Pharmaceuticals continues to explore the vast potential of orexin receptor 2 (OX2R) agonists, seeking to create best-in-class treatments that significantly enhance patients' lives. They are also investigating other applications, including addressing symptoms like cognitive deficits, fatigue, and impaired attention.
Company Overview
Centessa Pharmaceuticals plc is on a mission to discover and develop transformative therapies for patients. Their commitment to advancing innovative treatments is evident in their robust portfolio focused on sleep-wake disorders and immuno-oncology. Through their proprietary LockBody technology platform, they are exploring new frontiers in cancer therapy as well.
Contact Information
For more information about Centessa Pharmaceuticals and their ongoing projects, please reach out to Kristen K. Sheppard, Esq., Senior Vice President of Investor Relations at investors@centessa.com.
Frequently Asked Questions
What is ORX750?
ORX750 is a novel orexin receptor 2 (OX2R) agonist being researched for the treatment of sleep-wake disorders, including narcolepsy types 1 and 2, and idiopathic hypersomnia.
Where will the Phase 1 data be presented?
The data will be showcased at the American Academy of Neurology (AAN) 2025 Annual Meeting in San Diego.
Who is presenting the ORX750 data?
The data will be presented by Deborah Hartman, PhD, who is the Global Scientific Head of the Orexin Program at Centessa.
What potential conditions could ORX750 help treat?
ORX750 has potential applications in treating narcolepsy, excessive daytime sleepiness, and possibly other sleep-related or cognitive symptoms.
How can I stay updated on Centessa Pharmaceuticals' research?
You can subscribe to their updates and reach out via email or check their website for the latest news and developments.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.